ArticleBlood advances2023

Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.

Milos D Miljkovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.